中华胃肠外科杂志
中華胃腸外科雜誌
중화위장외과잡지
CHINESE JOURNAL OF GASTROINTESTINAL SURGERY
2011年
4期
261-263
,共3页
结直肠肿瘤%胰岛素抵抗%代谢综合征
結直腸腫瘤%胰島素牴抗%代謝綜閤徵
결직장종류%이도소저항%대사종합정
Colorectal neoplasms%Insulin resistance%Metabolic syndrome
目的 探讨结直肠癌患者是否存在胰岛素抵抗及其临床意义.方法 前瞻性收集2007年6月至2010年6月间温州医学院附属第三医院135例结直肠癌患者作为结直肠癌组,选择同期进行查体的120名健康人为对照组,测量身高、体质量、血压,抽空腹血测量血糖、三酰甘油、HDL-C和胰岛素,计算胰岛素抵抗指数(lnHOMA-IR).结果 结直肠癌组和对照组胰岛素抵抗指数分别为0.84±0.38和0.42±0.08,代谢综合征发生率分别为34.1%(46/135)和22.5%(27/120),差异均有统计学意义(P＜0.05).结直肠癌代谢综合征与非代谢综合征患者的胰岛素抵抗指数分别为0.98±0.41和0.74±0.22,差异无统计学意义(P＞0.05).胰岛素抵抗指数与结直肠癌分化程度、浸润深度、淋巴结转移、远处转移及TNM分期均无关(P＞0.05).结论 结直肠癌患者存在胰岛素抵抗,原因可能与代谢综合征及肿瘤本身有关.
目的 探討結直腸癌患者是否存在胰島素牴抗及其臨床意義.方法 前瞻性收集2007年6月至2010年6月間溫州醫學院附屬第三醫院135例結直腸癌患者作為結直腸癌組,選擇同期進行查體的120名健康人為對照組,測量身高、體質量、血壓,抽空腹血測量血糖、三酰甘油、HDL-C和胰島素,計算胰島素牴抗指數(lnHOMA-IR).結果 結直腸癌組和對照組胰島素牴抗指數分彆為0.84±0.38和0.42±0.08,代謝綜閤徵髮生率分彆為34.1%(46/135)和22.5%(27/120),差異均有統計學意義(P＜0.05).結直腸癌代謝綜閤徵與非代謝綜閤徵患者的胰島素牴抗指數分彆為0.98±0.41和0.74±0.22,差異無統計學意義(P＞0.05).胰島素牴抗指數與結直腸癌分化程度、浸潤深度、淋巴結轉移、遠處轉移及TNM分期均無關(P＞0.05).結論 結直腸癌患者存在胰島素牴抗,原因可能與代謝綜閤徵及腫瘤本身有關.
목적 탐토결직장암환자시부존재이도소저항급기림상의의.방법 전첨성수집2007년6월지2010년6월간온주의학원부속제삼의원135례결직장암환자작위결직장암조,선택동기진행사체적120명건강인위대조조,측량신고、체질량、혈압,추공복혈측량혈당、삼선감유、HDL-C화이도소,계산이도소저항지수(lnHOMA-IR).결과 결직장암조화대조조이도소저항지수분별위0.84±0.38화0.42±0.08,대사종합정발생솔분별위34.1%(46/135)화22.5%(27/120),차이균유통계학의의(P＜0.05).결직장암대사종합정여비대사종합정환자적이도소저항지수분별위0.98±0.41화0.74±0.22,차이무통계학의의(P＞0.05).이도소저항지수여결직장암분화정도、침윤심도、림파결전이、원처전이급TNM분기균무관(P＞0.05).결론 결직장암환자존재이도소저항,원인가능여대사종합정급종류본신유관.
Objective To investigate whether insulin resistance exists in patients with colorectal cancer and its clinical significance. Methods A total of 135 patients with colorectal cancer were included as the study group, and 120 healthy subjects were included as the control group. Height,weight, and blood pressure were recorded. Fasting plasma glucose, triglycerides, high-density lipoprotein cholesterol (HDL-C), and insulin were measured. Insulin resistance index (InHOMA-IR) was calculated. Results The lnHOMA-IR was 0.84±0.38 in the study group and 0.42±0.08 in the control group (P＜0.05). The incidence of metabolic syndrome was 34.1%(46/135) in the study group and 22.5%(27/120) in the control group (P＜0.05). Insulin resistance index did not differ between the groups according to metabolic syndrome (0.98±0.41 vs. 0.74±0.22, P＞0.05). There were no significant associations between insulin resistance index and tumor differentiation, depth of invasion, lymph node metastasis, distant metastasis, and TNM staging(P＞0.05). Conclusion Insulin resistance exists in colorectal cancer patients, and it is possibly associated with metabolic syndrome and the tumor.
